Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
JMP Securities initiated coverage on BeiGene Ltd , noting the Chinese biotech firm as a ‘unique investment opportunity.’
The company’s flagship drug, Brukinsa (zanubrutinib), is among the more recent BTK inhibitors to break into a global market projected to hit $12.2 billion by 2031. Three major players dominate this sector, with Johnson & Johnson‘s Imbruvica leading the charge, peaking at $8.7 billion in sales in 2021.
However, competition intensified when AstraZeneca Plc‘s Calquence and Brukinsa entered the market in 2017 and 2019, respectively.
Analyst Reni Benjamin’s confidence in Brukinsa emerging as a market leader is bolstered by an exclusive survey of 37 doctors, indicating that 80% plan to boost their use of Brukinsa due to its perceived safety and long-term effectiveness advantages.
As Imbruvica’s popularity declines, Calquence and Brukinsa will capture a larger market share. By 2031, Brukinsa is expected to command 55% of the market, potentially generating global sales of $5.4 billion, the analyst adds.
Benjamin says Brukinsa is on track to generate over $2 billion for the company in 2024, with total revenues to reach $3.7 billion.
The analyst has initiated the coverage with a Market Perform rating and a price target of $288.
China ranks as the third-largest healthcare market globally, behind the U.S. and the EU, with expenditures reaching $1.2 trillion.
BeiGene, which offers 14 products in China through various U.S. partners, holds a significant position in this market. Despite limited visibility into China’s regulatory and commercial environment, BeiGene’s sales force has driven annual revenues from China to $1.1 billion.
However, JMP writes that the numbers can drop to $178 million by 2031 due to patent expirations unless additional therapeutics are licensed.
Price Action: BGNE stock is up 1.05% at $199.59 at last check Wednesday.
Read Next:
Photo: Shutterstock
Latest Ratings for BGNE
Date | Firm | Action | From | To |
---|---|---|---|---|
Feb 2022 | Morgan Stanley | Maintains | Overweight | |
Feb 2022 | SVB Leerink | Maintains | Outperform | |
Jan 2022 | Morgan Stanley | Maintains | Overweight |
View More Analyst Ratings for BGNE
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Health care stocks were steady premarket Tuesday as the Health Care Select Sector SPDR Fund and iShares Biotechnology ETF were recently inactive.
AC Immune SA shares advanced nearly 6% after the company said it will receive a second milestone payment of 24.6 million Swiss francs ($29.1 million) under its agreement with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Henry Schein shares were over 2% higher after the company said it reached an agreement to be the exclusive distributor of Swiss company vVARDIS' drill-free Curodont Repair Fluoride Plus product to larger dental service organizations in the US.
BridgeBio Pharma shares were up more than 2% after the company said the US Food and Drug Administration has granted Breakthrough Therapy Designation to oral infigratinib, which the biopharmaceutical company is developing to treat children with achondroplasia.
Health care stocks were steady premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) were recently inactive.
AC Immune shares advanced by over 5% after the company said it would receive a second milestone payment of 24.6 million Swiss francs ($29.1 million) under its agreement with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Shares of Intuitive Surgical ISRG have risen 14.2% in the past three months, outperforming the Zacks Medical - Instruments industry’s growth of 3.8% and the broader Zacks Medical sector’s return of 5.4%. ISRG stock has risen 45.7% year to date, primarily due to strong demand for its robotic surgery procedures.
The uptrend is likely to continue for the rest of 2024 as improving da Vinci procedures should continue to attract investors going forward. The company’s newly launched da Vinci 5 is also showing strong uptake since its launch in March.
Moreover, ISRG expects da Vinci 5’s advanced imaging to drive market penetration and open new targeted segments. The significant growth in ISRG’s Ion procedures shows prospects for continued top-line improvement in the upcoming quarters.
The company’s continued focus on upgrading its systems has played a pivotal role in sustaining its growth. The systems’ minimally invasive nature has helped in the wide adoption of certain surgical procedures.
Meanwhile, ISRG’s shares are trading above the 50-day and the 200-day moving average, indicating a bullish trend.
ISRG Stock Trades Above 50-Day Average
Intuitive Surgical expects procedure volume to grow 14-17% in 2024, continuing to drive the top line higher. The demand for medical procedures began to rebound in 2023 following the COVID-19 disruption. This resulted in strong growth.
Although procedure volume continues to improve, the company’s growth expectation for its procedures for fiscal 2024 is slightly below the pre-pandemic growth rate of 18% for full-year 2019. The Zacks Consensus Estimate for 2024 revenues reflects a year-over-year improvement of 13.7%.
The strong growth in procedure volume is likely to continue in the upcoming quarters due to the rising demand for da Vinci 5 on the back of its advanced features and shorter console time. The new device has covered only 10% of its targeted market, giving it enough space for growth.
Meanwhile, robotic procedures are leading to clinical and cost benefits for its users, driving strong adoption. ISRG’s broad product portfolio and flexible financing options are helping the company to ward off strong competition in the industry. The recovering catheter supply for ISRG’s another robotic system, Ion modulation system, bodes well.
However, the procedure growth rate may get hurt during the second half, reflecting the increased adverse impact of soft demand for bariatric procedures and increasing headwinds in Asia from prolonged physician strikes in Korea, delayed tenders and emerging domestic robotic systems in China. The company has maintained its guidance for full-year 2024.
ISRG expects gross margin in 2024 to be 68.5-69%, higher than 68% in 2023. The growth should be primarily driven by the strong uptake of da Vinci 5, improving supply challenges and realization of lower cost of materials. Moreover, the company lowered its operating expenses growth estimate to 10-13% from 11-15% (projected during the first-quarter earnings call).The improvement in costs and expenses is likely to drive earnings higher during the second half of 2024.
The Zacks Consensus Estimate for 2024 earnings is currently pegged at $6.67 per share, indicating a 16.8% year-over-year improvement. The estimate improved 6.5% over the past 60 days.
Expanding Portfolio Aids Long-term Prospects
ISRG’s expanding portfolio aids long-term prospects. In March, it received FDA approval for its da Vinci 5 fifth-generation multiport robotic system. The newest member of the da Vinci family is da Vinci 5, which also comprises the single-port da Vinci SP and the multiport da Vinci X and Xi systems. This was followed by FDA 510(k) clearance of a labeling revision for its da Vinci X and Xi specific to radical prostatectomy in June.
These clearances are likely to boost Intuitive Surgical’s business and generate additional revenues with new installations and wider procedure support. The installed base of the da Vinci system grew approximately 14% year over year during the second quarter of 2024.
Apart from da Vinci systems, Intuitive Surgical launched the Ion endoluminal system in 2019, extending its commercial offering beyond surgery into diagnostic endoluminal procedures. The system received approval in Europe and South Korea in 2023. It received approval in China during the first quarter of 2024.
Per the second-quarter 2024 earnings call, the installed base of Ion modulation system grew approximately 56% year over year to 678 units. The company completed approximately 23,200 Ion procedures in the second quarter, reflecting year-over-year growth of 82%.
Challenging Market Scenario Persists
Although ISRG has a strong product portfolio with significant opportunities, the company faces huge competition from large and well-established companies, such as Johnson & Johnson JNJ and Medtronic MDT, which are also focused on developing robotically controlled products. These companies have strong balance sheets and commercial networks to support the development and launch of new products. This can significantly affect ISRG’s prospects.
Meanwhile, any rise in supply-chain issues amid continuing geopolitical tensions may lead to choppy da Vinci 5 system placements in 2024. Any setback to recovering catheter supply may adversely impact Ion modulation system sales. Moreover, weakness in bariatric procedures, along with challenges in China from increasing provincial robotic competition and delayed tenders affecting capital placements, is likely to have a nearly three percentage point headwind for revenues in 2024.
Wrapping Up
Intuitive Surgical’s top and bottom-line performances are likely to remain strong in 2024 on the back of continued growth in the company’s da Vinci procedure volume, coupled with strong Ion procedure growth. ISRG is also increasing the pricing of procedures that should aid in 2024 sales growth. Improving procedure volume, along with better system placements and services across all markets, should drive top-line growth this year.
The launch of da Vinci SP in Europe and da Vinci 5 in the U.S. market should drive system placements higher. However, ongoing supply-chain constraints, although easing, are likely to hurt the availability of devices. Weakness in bariatric procedures and challenges in China are likely to offset growth in the upcoming quarters.
Although ISRG carries a favorable Zacks Rank at present, its style scores don’t look quite promising. The company has a Value score of F and Momentum and Growth scores of D and C, respectively. As such, we believe that investors should not rush into buying the stock now. While current shareholders should hold their position, new investors should wait for the stock to retract some of its recent gains, providing an attractive valuation for entry.
ISRG YTD Performance
Intuitive Surgical currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Investment Research
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.